Key Takeaway: The article discusses the safety profile of Arimoclomol in treating Niemann-Pick disease type C (NPC) based on long-term data from an expanded access program in the USA. This data was presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium. The findings suggest a favorable safety profile for the drug in a real-world setting.
Price reaction · baseline $7.19 (2024-09-04 close) · hit pre-market · 2 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term data indicates a favorable safety profile for Arimoclomol.
The study contributes valuable real-world evidence for NPC treatment.
Expanded access program allows more patients to receive treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol Safety Profile in the Treatment of NPC in a Real-World Setting: Long-Term Data From an Expanded Access Program in the USA
Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium - 09/06/2024
Download PDF
Download PDF
Frequently Asked Questions
What is the safety profile of Arimoclomol?
Arimoclomol has a favorable safety profile based on long-term data.
What disease does Arimoclomol treat?
Arimoclomol is used in the treatment of Niemann-Pick disease type C (NPC).
Where was the data on Arimoclomol presented?
The data was presented at the SSIEM 2024 Annual Symposium.
What type of program provided data for Arimoclomol?
Data was collected from an expanded access program in the USA.